Diagonal Bio AB (publ)

OM:DIABIO Stock Report

Market Cap: SEK 10.3m

Diagonal Bio Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of DIABIO?
Owner TypeNumber of SharesOwnership Percentage
Institutions35,958,5268.97%
Private Companies36,449,0849.1%
Individual Insiders139,856,39834.9%
General Public188,450,20547%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 902.4%.

Top Shareholders

Top 21 shareholders own 52.97% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12.2%
Stig Aune
48,750,000SEK 1.3m79.2%no data
5.36%
Nordnet Pensionsförsäkring Ab, Asset Management Arm
21,482,389SEK 554.2k28%0.01%
3.61%
Avanza Fonder AB
14,470,159SEK 373.3k-3.83%no data
3.36%
JSH Biotech ApS
13,450,480SEK 347.0k0%no data
2.66%
Henrik Nilsson
10,657,930SEK 275.0k0%no data
2.5%
Svante Olofsson
10,000,867SEK 258.0k0%no data
2.5%
Sarsaparill AB
10,000,000SEK 258.0k0%no data
2.43%
Juha Kauppinen
9,756,666SEK 251.7k0%no data
2.4%
Dick Södergren
9,633,448SEK 248.5k597%no data
2.36%
Anders Haskel
9,450,480SEK 243.8k0%no data
2.36%
Tommy Ure
9,450,480SEK 243.8k0%no data
2.05%
Ismail Arian
8,200,000SEK 211.6k-14.1%no data
2%
Paginera Invest Ab
8,000,000SEK 206.4k0%no data
2%
Martin Milanov
8,000,000SEK 206.4k0%no data
1.6%
Ylber Rexhepi
6,418,097SEK 165.6k324%no data
1.55%
Christofer Bergstrand
6,230,000SEK 160.7k482%no data
1.25%
Latimo AB
4,998,604SEK 129.0k0%no data
0.5%
Kushagr Punyani
1,986,292SEK 51.2k0%no data
0.23%
Andreas Nyberg
927,528SEK 23.9k0%no data
0.098%
Per Heander
394,610SEK 10.2k0%no data
0.0015%
FCG Fonder AB
5,978SEK 154.00%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 11:06
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Diagonal Bio AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution